PCL-5: PTSD Checklist for DSM-5

What is the PCL-5?

The PCL-5 (PTSD Checklist for DSM-5) is a 20-item self-report measure that assesses the severity of post-traumatic stress disorder symptoms. Developed by the National Center for PTSD (Weathers, Litz, Keane, and colleagues), it was updated from earlier versions (PCL-C, PCL-S) to align with the DSM-5 diagnostic criteria for PTSD.

Each item maps directly to one of the 20 DSM-5 PTSD symptoms, organized across four symptom clusters: intrusion, avoidance, negative alterations in cognitions and mood, and alterations in arousal and reactivity. Respondents rate how much they have been bothered by each symptom in the past month on a 0-to-4 scale.

The PCL-5 is freely available from the National Center for PTSD with no permission or licensing fees required for clinical or research use. It takes 5 to 10 minutes to complete.

PCL-5 Scoring & Clinical Cutoffs

Each item is rated from 0 (not at all) to 4 (extremely). Total scores range from 0 to 80. The most commonly used clinical cutoff is 31 to 33, with 33 being the standard threshold for a probable PTSD diagnosis in most research settings.

When tracking treatment response, a 5-point change is considered clinically meaningful, and a 10-point change indicates reliable change (i.e., change beyond measurement error). These thresholds help clinicians distinguish genuine improvement from normal score fluctuation.

DSM-5 Symptom Clusters

The PCL-5's 20 items map to four DSM-5 PTSD symptom clusters. Understanding the cluster structure helps clinicians identify which symptom domains are most elevated and track differential treatment response across domains.

A provisional PTSD diagnosis using the PCL-5 requires at least 1 Cluster B item, 1 Cluster C item, 2 Cluster D items, and 2 Cluster E items each rated 2 (moderately) or higher, in addition to meeting the total score cutoff.

Clinical Applications

The PCL-5 serves multiple clinical functions. As a screening tool, it identifies individuals likely to meet diagnostic criteria for PTSD, informing decisions about whether to pursue a full diagnostic assessment such as the Clinician-Administered PTSD Scale (CAPS-5).

In treatment monitoring, the PCL-5 is typically administered monthly or at each session. The cluster-level scoring is particularly valuable here — a client in prolonged exposure therapy might show early improvement in Cluster C (avoidance) as they engage with trauma material, while Cluster E (arousal) symptoms may take longer to resolve. Tracking these differential trajectories helps clinicians gauge whether treatment is progressing as expected.

The PCL-5 can be administered with or without a Criterion A event anchor. The anchored version asks respondents to identify a specific traumatic event and rate symptoms in relation to that event, which is more specific but may miss symptoms related to other traumas. The unanchored version captures overall PTSD symptom burden regardless of source.

Reliability & Validity

The PCL-5 demonstrates excellent internal consistency (Cronbach's alpha = 0.94 to 0.97 across studies) and strong test-retest reliability (r = 0.82 to 0.84 over one week). It shows high convergent validity with the CAPS-5, the gold-standard clinician-administered PTSD assessment.

At the cutoff score of 33, the PCL-5 achieves approximately 88% sensitivity and 69% specificity for PTSD diagnosis. The measure has been validated in veteran, military, and civilian trauma populations across multiple countries and languages.